Cocrystal Pharma, Inc.COCPNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +0.21% | +0.00% | +0.00% | +0.00% | +8.03% |
| Weighted Average Shares Diluted Growth | +0.21% | +0.00% | +0.00% | +0.00% | +8.03% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +36.52% | +44.07% | +52.46% | -21.32% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -50.23% | -56.95% | -59.85% | -60.58% | -35.65% |
| Book Value per Share Growth | -58.69% | -63.91% | -67.66% | -69.33% | -44.12% |
| Debt Growth | +1488.98% | -2.54% | -4.88% | -6.85% | -15.57% |
| R&D Expense Growth | -22.70% | -52.26% | -53.90% | -73.96% | -70.57% |
| SG&A Expenses Growth | -2.65% | -16.73% | -18.79% | -13.51% | -37.67% |